Clinical trials: Mild Alzheimer Disease
Alzheimer's Disease
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease
The purpose of this study is to determine in a 12-week treatment study if MEM 1003 is a safe and effective treatment for patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00257673
- Testing
- MEM 1003
- Where
- 57 sites in United States
- Volunteers
- 183 people
- Sponsor
- Memory Pharmaceuticals
Alzheimers Disease, Mild Cognitive Impairment
Non-expensive and Widely Available Tests as Diagnostic Tools in Dementia and Their Ability to Predict Disease Progression
Alzheimers disease (AD) is the most common course of cognitive decline and thereby the course of more than half of all cases of dementia.
- Trial name
- DEMPROG (NCT01642420)
- Where
- Denmark
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- Zealand University Hospital
Alzheimer Disease
Gamma-Music Based Intervention for Mild Alzheimer's Disease
The study will test and refine a novel brain-stimulation tool using gamma-frequency lights coupled with self-selected music for a gamma-music-based intervention for participants with mild Alzheimer's Disease.
- Trial name
- NUGammaMBI (NCT05984524)
- Testing
- Gamma-Music Based Intervention
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Northeastern University
Mild Cognitive Impairment, Alzheimer Disease
Senicapoc in Alzheimer's Disease
Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD.
- Trial name
- Senicapoc (NCT04804241)
- Testing
- Senicapoc
- Where
- 2 sites in United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Alzheimer Disease, Mild Cognitive Impairment
Brain Energy Metabolism and Sleep in Adults
The three primary goals of this pilot will be followed by a secondary goal to test if dental intervention improves brain health in terms of sleep and cognition. The primary and secondary goals are 1.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Cognitive Change, Energy Metabolism
- Trial name
- NCT03929302
- Testing
- MyTAP oral appliance plus mouth shield
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- The University of Texas at Dallas
Alzheimer Disease, Preclinical Alzheimer's Disease
Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech
The primary objective of the study is to evaluate whether a set of algorithms analysing acoustic and linguistic patterns of speech can detect amyloid-specific cognitive impairment in early stage Alzheimer's disease, as measured…
- Conditions
- Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes)
- Trial name
- AMYPRED (NCT04828122)
- Where
- 4 sites in United Kingdom
- Volunteers
- 141 people, healthy volunteers welcome
- Sponsor
- Novoic Limited
Alzheimer's Disease
Enhancing Neuroplasticity and Frontal Lobe Function in Patients With Mild Alzheimer's Disease
The purpose of this study is to determine if a novel brain stimulation approach using magnetic stimulation (Transcranial Magnetic Stimulation [TMS]) can improve memory and thinking processes in individuals with mild Alzheimer's…
- Trial name
- TMS-AD (NCT01847586)
- Testing
- Paired Associative Stimulation, Paired Associative Stimulation-Control
- Where
- Canada
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Alzheimer Disease, Aging
Vanderbilt Memory and Aging Project
This study will use an observational cohort to cross-sectionally and longitudinally relate vascular health to clinical, imaging, and biological markers of early Alzheimer's disease and cerebrovascular disease among aging adults.
- Conditions
- Alzheimer Disease, Aging, Aged, 80 and Over, Biomarkers
- Trial name
- VMAP (NCT05372159)
- Testing
- none, observational study
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Vanderbilt University Medical Center
Mild Cognitive Impairment (MCI), Mild Alzheimer Disease
A Study To Assess The Feasibility Of Indivi Mobile Application In Monitoring Cognitive Performance In Aging Population
The goal of this observational study is to evaluate the functionality and usability of Indivi mobile application-based cognitive activities in people with mild cognitive impairment/mild Alzheimer's disease (PwMCI/AD) and healthy…
- Trial name
- ADAPT-MCI-01 (NCT07174869)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Indivi AG
Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI)
Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance
Alzheimer's disease causes progressive memory and cognitive decline, driven in part by the buildup of a protein called β-amyloid in the brain.
- Trial name
- NCT07456462
- Testing
- MRI assessment and blood sample collection
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS San Raffaele
Alzheimer's Disease
Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)
To evaluate the tolerability, safety and efficacy of 3-step titration versus 1-step titration of Rivastigmine patch in the Japanese population.
- Trial name
- NCT01614886
- Testing
- Active Comparator, ENA713
- Where
- 50 sites in Japan
- Volunteers
- 216 people
- Sponsor
- Novartis Pharmaceuticals
Subjects With Mild Cognitive Impairment (MCI) of AD, Alzheimer's Disease (AD) Dementia
Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function
This study is to evaluate the efficacy and safety of [18F]-APN-1607 Injection in PET imaging for detecting AD-related cognitive impairment.
- Trial name
- NCT07422857
- Testing
- [18F]-APN-1607
- Where
- 2 sites in China
- Volunteers
- 316 people, healthy volunteers welcome
- Sponsor
- JYAMS PET Research & Development Limited
Alzheimer Disease, Amnestic-Mild Cognitive Impairment
Sustainable Method for Alzheimer's Prediction
This is an observational study with the aim of validating, in a consistent population sample, with appropriate follow-up, whether EEG connectivity analysis combined with the neuropsychological evaluation and ApoE genotype testing…
- Trial name
- NCT03654911
- Testing
- EEG, ApoE
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Catholic University of the Sacred Heart
Dementia, Early Onset, Alzheimer Dementia (AD)
Genetic Studies of Early-onset Dementia
The aim of this study is to identify genetic factors that contribute to risk and progression of early-onset dementia (loss of memory function before the age of 70 years) across all ethnic groups, including Alzheimer's Disease…
- Conditions
- Dementia, Early Onset, Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI), Memory Loss
- Trial name
- NCT04906863
- Testing
- Blood draw, Neurocognitive testing, Medical questionnaire
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Columbia University
Exercise, Gait
Rhythmically Entrained Exercise in Community-Dwelling Older Adults
Researchers at the University of North Carolina at Greensboro conduct a single-arm intervention trial to investigate the efficacy of a music-based group exercise program for community-dwelling older adults.
- Conditions
- Exercise, Gait, Cognitive Decline, Caregiver Burden
- Trial name
- REECO (NCT05462977)
- Testing
- Group exercise program
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Greensboro
Alzheimer's Disease
A Trial of SK-PC-B70M in Mild to Moderate Alzheimer's Disease
The purpose of this study is to find optimistic dose and to evaluate the efficacy and safety of SK-PC-B70M in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT00443417
- Testing
- SK-PC-B70M
- Where
- South Korea
- Volunteers
- 188 people
- Sponsor
- SK Chemicals Co., Ltd.
Dementia, Dysphagia
Family Caregiver Online Survey (Dementia and Swallowing Difficulties)
The Family Caregiver Survey is a one-time, 30-minute, online survey for people living with and caring for a family member with dementia.
- Conditions
- Dementia, Dysphagia, Dementia Alzheimers, Dementia, Vascular
- Trial name
- NCT06471660
- Where
- United States
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- University of Oregon
Alzheimer Disease
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo.
- Trial name
- NCT00667810
- Testing
- bapineuzumab
- Where
- 346 sites in United States, Argentina and 24 more
- Volunteers
- 901 people
- Sponsor
- Pfizer
Alzheimer Disease, Cognitive Dysfunction
Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type
A Randomized Pivotal Study of RenewTM NCP-5 for the Treatment of Mild Cognitive Impairment due to Alzheimer's Disease or Mild Dementia of the Alzheimer's Type is a pivotal, single blind, parallel design, multi-site study intends…
- Conditions
- Alzheimer Disease, Cognitive Dysfunction, Mild Cognitive Impairment, Mild Dementia
- Trial name
- NCT03721705
- Testing
- Renew NCP-5
- Where
- 12 sites in United States, Ireland and 1 more
- Volunteers
- 190 people
- Sponsor
- Renew Research, LLC
Alzheimer Disease
A Study to Assess Safety and Tolerability and to Explore Efficacy of NSC001 in Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety and tolerability of NSC001 on in patients with mild to moderate Alzheimer's disease and to evaluate the influence of the compound on cognitive function.
- Trial name
- NCT06995573
- Testing
- NSC001
- Where
- 10 sites in Austria, Germany
- Volunteers
- 90 people
- Sponsor
- NSC-Therapeutics